Fortis Healthcare promoted Agilus Diagnostics files DRHP with Sebi for IPO
Securities and Exchange Board of India (Sebi) to raise money from the primary markets.
The issue comprises offer for sale (OFS) aggregating up to 14,233,964 equity shares where International Finance Corporation l, NYLIM Jacob Ballas India Fund III LLC and Resurgence PE Investments will look to divest their stakes.
Under the OFS, International Finance Corporation will sell shares totaling up to 29.85 lakh, while NYLIM Jacob and Resurgence will sell up to 74.62 lakh and 37.86 lakh equity shares.
The face value of the shares is Rs 10 each.
The company which is promoted by Fortis Healthcare claims to be the largest diagnostics service provider in terms of number of laboratories and the second largest in terms of revenue from operations in India as of March 31, 2023 for the said financial year.
The shares will be listed on the BSE and NSE, a company release said.
ICICI Securities Limited, Axis Capital Limited & Citigroup Global Markets India Private Limited are the Book Running Lead Managers to the issue while the registrar for the issue is KFin Technologies Limited
The company reported a consolidated revenue of Rs 1,347.46 crore for the financial year ended March 31, 2023 which was down from Rs 1,604.91 crore the company reported in FY22 and up from 1,035.07 crore in FY21.
The consolidated profit stood at Rs 116.63 crore in FY23 versus Rs 554.7 in FY22 and crore in Rs 131.24 crore FY21.
The net worth of the company stood at Rs 1,803.76 crore at the end of FY23 versus Rs 1,724.34 crore in FY22 and 1,169.57 crore in FY21, the DRHP said.
